What keeps PL up at night...What keeps PL up at night is the fear of being taken out under $10 per share.
What keeps me up at night is the fact that no one has taken a run at us yet. Not at $8, not at $5, not at $2, not even at $1! lol
After this $25 million financing, which by the way will cost PLI $37.5 million at term and a dilution of 10+ million shares to shareholders (basically a 50% GIC for Thomvest), PLI needs to deliver a deal. Someone just mentionned it, and many will agree that a regional deal is the missing piece of the puzzle. We need to see with our own eyes (and money) that someone is interested by what we have.
I really appreciate Thomvest for supporting PLI, but there are no friends in this business (their financings are always very expensive, both on the company and on the shareholders), and will not propel the company anywhere by forking money out. I think IR needs to do a better job at finding investors, deep pocketed ones that is, so that a few can fight for financing rights. Those terms at 8.5% yearly compounded interest are not good. If we had a few whealty investors, they could battle it out at say 2.5%, $7.50 warrants (instead of $3.70), and a shorter term to exercise. Right now, Thomvest's got PLI by the "bowls".
PLI seems to have a tremendously strong pipeline, but no great sign of interest on the stock. So far the powers that be seem to be happy making money trading the title. We need strong hands that won't trade it, but hold strong to see this through.
I don't call a miracle drug going through trials with good to great data, "delivering" from management. The drug does that on it's own. Getting a deal done and finding strong investors are "delivering" in my books, but we have yet to see any of this. The company definitely has to start delivering.
For those who may think that getting plasminogen approved will get us to the next level, just remember that when the sales start, they can't afford to disapoint the shareholders (we have high expectations), and that the next quarter will have to show growth. If sales are low and the next quarter does not show growth, down we will go again. Plasminogen is only the beginning of an uphill battle to rise this company to star status.
I do believe they have everything needed to deliver something great, but they need to do it soon.
From a long